CANSINOBIO (06185) entered into a strategic cooperation framework agreement with DePuShi Biotechnology for the joint development of an mRNA personalized therapeutic tumor vaccine.

CANSINOBIO (06185) released an announcement, stating that the company has noted recent developments in the mRNA technology market. The mRNA platform is one of the key technology platforms that the company is focusing on. The company is currently developing mRNA vaccines for prevention and therapeutic biological products, as well as related delivery systems. In the area of therapeutics, the company is advancing research and development of mRNA vaccines for indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of In Vivo CAR-related therapies, which are currently in the early stages. Recently, the companys subsidiary CanSino Biologics Inc. (Shanghai) Biopharmaceutical Research Co., Ltd. (CanSino Biologics Inc. Shanghai) entered into a strategic cooperation framework agreement for the joint development of mRNA personalized therapeutic tumor vaccines with Depsey (Hangzhou) Biotechnology Co., Ltd. (Depsey Biotech). According to the strategic cooperation framework agreement, the two parties will leverage their respective advantages in mRNA vaccine technology and the discovery and design of new tumor antigens to explore collaboration. The board of directors believes that the development of the companys mRNA technology platform and the signing of the strategic cooperation framework agreement align with the long-term strategy of the company and are in the overall interests of the company and its shareholders.